Trust Investment Advisors Invests $1.03 Million in Globus Medical, Inc. $GMED

Trust Investment Advisors acquired a new position in shares of Globus Medical, Inc. (NYSE:GMED) in the first quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 11,928 shares of the medical device company’s stock, valued at approximately $1,028,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Advisory Services Network LLC purchased a new position in Globus Medical during the third quarter worth about $26,000. EverSource Wealth Advisors LLC raised its stake in shares of Globus Medical by 74.3% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 462 shares of the medical device company’s stock valued at $27,000 after acquiring an additional 197 shares during the period. SBI Securities Co. Ltd. lifted its holdings in shares of Globus Medical by 98.2% in the 4th quarter. SBI Securities Co. Ltd. now owns 337 shares of the medical device company’s stock worth $29,000 after acquiring an additional 167 shares during the last quarter. Parallel Advisors LLC lifted its holdings in shares of Globus Medical by 45.1% in the 3rd quarter. Parallel Advisors LLC now owns 557 shares of the medical device company’s stock worth $32,000 after acquiring an additional 173 shares during the last quarter. Finally, Headlands Technologies LLC boosted its position in shares of Globus Medical by 485.4% during the 2nd quarter. Headlands Technologies LLC now owns 761 shares of the medical device company’s stock worth $45,000 after purchasing an additional 631 shares during the period. 95.16% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

GMED has been the subject of several research reports. Royal Bank Of Canada lifted their target price on shares of Globus Medical from $115.00 to $120.00 and gave the company an “outperform” rating in a report on Friday, May 8th. Wall Street Zen downgraded Globus Medical from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 9th. Wells Fargo & Company cut their price target on shares of Globus Medical from $104.00 to $103.00 and set an “overweight” rating on the stock in a research note on Friday, May 8th. Weiss Ratings reissued a “hold (c+)” rating on shares of Globus Medical in a research report on Wednesday, April 15th. Finally, Needham & Company LLC raised their price objective on shares of Globus Medical from $114.00 to $117.00 and gave the company a “buy” rating in a research note on Friday, May 8th. Two research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $105.00.

Globus Medical Price Performance

Globus Medical stock opened at $75.99 on Thursday. Globus Medical, Inc. has a 1-year low of $51.79 and a 1-year high of $101.40. The stock has a market cap of $10.32 billion, a PE ratio of 17.67, a P/E/G ratio of 1.63 and a beta of 0.95. The stock’s fifty day moving average is $82.66 and its two-hundred day moving average is $87.22.

Globus Medical (NYSE:GMED) last announced its quarterly earnings results on Thursday, May 7th. The medical device company reported $1.12 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.92 by $0.20. Globus Medical had a return on equity of 13.46% and a net margin of 18.92%.The company had revenue of $759.85 million during the quarter, compared to the consensus estimate of $740.35 million. During the same period in the previous year, the business earned $0.68 EPS. Globus Medical’s revenue for the quarter was up 27.0% on a year-over-year basis. Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS. On average, research analysts expect that Globus Medical, Inc. will post 4.74 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, Director David D. Davidar sold 25,000 shares of the company’s stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $80.76, for a total value of $2,019,000.00. Following the completion of the transaction, the director directly owned 510,175 shares of the company’s stock, valued at $41,201,733. This represents a 4.67% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 18.38% of the stock is currently owned by insiders.

Globus Medical Company Profile

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.